• Age: ≥ 18 years old and ≤ 65 years old, male or female, subjects voluntarily participate in this clinical study and sign the Informed Consent Form (ICF)

• Previous diagnosis of systemic lupus erythematosus (SLE) (according to the 1997 American Rheumatology Association criteria)

• Females of childbearing potential must use effective contraception during study treatment and for 90 days after the last dose of study treatment. In addition, subjects must not donate eggs during the study and for at least 90 days after the last dose of study treatment

• Subjects with Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) score ≥ 8 points prior to screening

• Subject has ≥ 1 organ system with BILAG-2004 Class A mobility score or ≥ 2 organ systems with BILAG-2004 Class B mobility score prior to screening

• Subjects meets one of the following:

‣ Antinuclear antibody (ANA) ≥ 1:80, determined by immunofluorescence method;

⁃ Anti-dsDNA antibodies are higher than normal level;

⁃ Anti-Smith antibodies are higher than normal level

• Absolute number of neutrophils ≥ 1.0×10\^9/L, hemoglobin ≥ 60g/L

• Left ventricular ejection fraction (LVEF) ≥ 50%

• Subjects have been treated with oral corticosteroids (OCS) in combination with an immunosuppressive or biologic agent for at least 6 months prior to enrollment